nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.0843	0.0843	CbGpPWpGaD
Mivacurium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.0838	0.0838	CbGpPWpGaD
Mivacurium—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.0398	0.0398	CbGpPWpGaD
Mivacurium—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.0339	0.0339	CbGpPWpGaD
Mivacurium—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.0322	0.0322	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.0299	0.0299	CbGpPWpGaD
Mivacurium—BCHE—Peptide hormone metabolism—CGA—conduct disorder	0.0282	0.0282	CbGpPWpGaD
Mivacurium—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0259	0.0259	CbGpPWpGaD
Mivacurium—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0256	0.0256	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.0255	0.0255	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.0242	0.0242	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—GABRA2—conduct disorder	0.0229	0.0229	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0218	0.0218	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0216	0.0216	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—GABRA2—conduct disorder	0.0195	0.0195	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—GABRA2—conduct disorder	0.0185	0.0185	CbGpPWpGaD
Mivacurium—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0169	0.0169	CbGpPWpGaD
Mivacurium—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0167	0.0167	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—COMT—conduct disorder	0.0144	0.0144	CbGpPWpGaD
Mivacurium—CHRND—Transmission across Chemical Synapses—MAOA—conduct disorder	0.0143	0.0143	CbGpPWpGaD
Mivacurium—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0142	0.0142	CbGpPWpGaD
Mivacurium—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0141	0.0141	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.0133	0.0133	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—COMT—conduct disorder	0.0123	0.0123	CbGpPWpGaD
Mivacurium—CHRNA1—Transmission across Chemical Synapses—MAOA—conduct disorder	0.0122	0.0122	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—COMT—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Mivacurium—CHRNA2—Transmission across Chemical Synapses—MAOA—conduct disorder	0.0116	0.0116	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.0115	0.0115	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.0114	0.0114	CbGpPWpGaD
Mivacurium—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0111	0.0111	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—COMT—conduct disorder	0.011	0.011	CbGpPWpGaD
Mivacurium—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.011	0.011	CbGpPWpGaD
Mivacurium—CHRND—Neuronal System—MAOA—conduct disorder	0.011	0.011	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—GABRA2—conduct disorder	0.0102	0.0102	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—COMT—conduct disorder	0.00939	0.00939	CbGpPWpGaD
Mivacurium—CHRNA1—Neuronal System—MAOA—conduct disorder	0.00932	0.00932	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—COMT—conduct disorder	0.00892	0.00892	CbGpPWpGaD
Mivacurium—CHRNA2—Neuronal System—MAOA—conduct disorder	0.00885	0.00885	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00787	0.00787	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00765	0.00765	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00757	0.00757	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00751	0.00751	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00743	0.00743	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—COMT—conduct disorder	0.00642	0.00642	CbGpPWpGaD
Mivacurium—BCHE—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00638	0.00638	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00616	0.00616	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00592	0.00592	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00582	0.00582	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00577	0.00577	CbGpPWpGaD
Mivacurium—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00533	0.00533	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—CGA—conduct disorder	0.00533	0.00533	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.005	0.005	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00495	0.00495	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—COMT—conduct disorder	0.00492	0.00492	CbGpPWpGaD
Mivacurium—BCHE—Neuronal System—MAOA—conduct disorder	0.00489	0.00489	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00483	0.00483	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00428	0.00428	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00424	0.00424	CbGpPWpGaD
Mivacurium—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00422	0.00422	CbGpPWpGaD
Mivacurium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00377	0.00377	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00329	0.00329	CbGpPWpGaD
Mivacurium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00326	0.00326	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00326	0.00326	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00326	0.00326	CbGpPWpGaD
Mivacurium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00299	0.00299	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00296	0.00296	CbGpPWpGaD
Mivacurium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00279	0.00279	CbGpPWpGaD
Mivacurium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00277	0.00277	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CGA—conduct disorder	0.00275	0.00275	CbGpPWpGaD
Mivacurium—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00256	0.00256	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00213	0.00213	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CGA—conduct disorder	0.00211	0.00211	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00211	0.00211	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.00184	0.00184	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00182	0.00182	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00177	0.00177	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00167	0.00167	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00166	0.00166	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00141	0.00141	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.0014	0.0014	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—COMT—conduct disorder	0.00124	0.00124	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—MAOA—conduct disorder	0.00123	0.00123	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.0012	0.0012	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00119	0.00119	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.00119	0.00119	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.00109	0.00109	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.00108	0.00108	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000989	0.000989	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000979	0.000979	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—COMT—conduct disorder	0.000953	0.000953	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—MAOA—conduct disorder	0.000946	0.000946	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000645	0.000645	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000639	0.000639	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—EP300—conduct disorder	0.000531	0.000531	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—EP300—conduct disorder	0.000409	0.000409	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000342	0.000342	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000338	0.000338	CbGpPWpGaD
